Vemurafenib May Be Effective in Relapsed, Refractory Hairy-cell Leukemia

Share this content:
A short course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia.
A short course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia.

A short course of vemurafenib, an oral BRAF inhibitor, was highly effective in patients with relapsed or refractory hairy-cell leukemia, a rare form of lymphocytic leukemia that shares some features with chronic lymphocytic leukemia (CLL), a new study published in The New England Journal of Medicine has shown.1

Because BRAF V600E is the underlying genetic mutation that drives hairy-cell leukemia, researchers sought to evaluate the activity and safety of vemurafenib in patients with relapsed or refractory disease by conducting 2 phase 2 studies, one in the United States and another in Italy.

For the studies, researchers enrolled 28 patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues in the Italian trial and 26 of 36 planned patients in the US trial.

All patients received vemurafenib 960 mg orally twice daily for a median of 16 weeks in the Italian study and 18 weeks in the US trial.

Results showed that the overall response rates were 96% and 100% among evaluable patients after a median of 8 weeks and 12 weeks in the Italian trial and the US trial, respectively.

Researchers found that 35% and 42% of patients in the Italian trial and the US trial, respectively, achieved a complete response. One-year progression free survival rate was 73% and 1-year overall survival rate was 91% in the US study.

RELATED: FCR Achieves Long-term Disease-free Survival in IGHV-mutated CLL

In regard to safety, the most common vemurafenib-associated adverse events leading to dose reductions with rash and arthralgia, but most side effects were grade 1 or 2.

The study also demonstrated that bypass reactivation of MEK and ERK may be a resistance mechanism for vemurafenib in this patient population.

Reference

  1. Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015; 373(18):1733-1747.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs